Verastem (VSTM) Cost of Revenue (2018 - 2026)

Verastem's (VSTM) quarterly Cost of Revenue came in at $2.8 million in Q1 2026, up 6.13% quarter-over-quarter from $2.6 million in Q4 2025.

Verastem (VSTM) Cost of Revenue (2018 - 2026) Analysis & Trends

Verastem's Cost of Revenue history runs 5 years deep, the most recent figure standing at $2.8 million for Q1 2026.

On a quarterly basis, Cost of Revenue changed N/A year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $7.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $4.6 million, changed N/A from the prior year.
Cost of Revenue rose to $2.8 million in Q1 2026 per VSTM's latest filing, from $2.6 million in the prior quarter.
Across five years, Cost of Revenue topped out at $2.8 million in Q1 2026 and bottomed at $318000.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	167.22 Mn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	392.80 Mn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	296.00 Mn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	145.00 Mn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Verastem	607.94 Mn	410.11 Mn	15.90 Mn	2.77 Mn

Download Data